breast-cancer

Tailored breast cancer radiotherapy achieves under 3% local recurrence rate at 10 years

Following breast cancer treatment, recurrence at the original tumor site (locoregional recurrence, LRR) is a significant concern. This Dutch registry study examined outcomes of a tailored radiotherapy approach where the extent of radiation to lymph nodes was guided by individual patient nodal…

Dan Manning

Dan Manning

— 1 min read
Share
Tailored breast cancer radiotherapy achieves under 3% local recurrence rate at 10 years

Tailored breast cancer radiotherapy achieves under 3% local recurrence rate at 10 years

Following breast cancer treatment, recurrence at the original tumor site (locoregional recurrence, LRR) is a significant concern. This Dutch registry study examined outcomes of a tailored radiotherapy approach where the extent of radiation to lymph nodes was guided by individual patient nodal response to treatment.

At 10-year follow-up, fewer than 3% of patients treated with this tailored approach experienced locoregional recurrence, and most recurrences happened in the first 5 years. Importantly, the overall LRR rate did not significantly differ based on how extensively lymph nodes were irradiated, suggesting that de-escalation of nodal radiation may be safe in some patients.

These results provide important long-term evidence supporting individualized, response-guided radiation approaches in breast cancer — potentially reducing side effects like lymphedema without compromising cancer control.

Key Findings

  • Locoregional recurrence rate of 2.9% at 10 years with tailored nodal radiotherapy
  • Most LRRs occurred within the first 5 years
  • LRR rate did not significantly differ based on extent of nodal irradiation
  • Dutch registry study providing real-world, long-term outcome data
  • Results support response-guided radiation de-escalation in appropriate breast cancer patients

Implications

These excellent 10-year outcomes validate tailored nodal radiotherapy approaches and may support further reduction of lymph node irradiation in low-risk breast cancer patients. Reducing nodal radiation could decrease lymphedema rates and other radiation toxicities without compromising locoregional control.

Caveats

News summary only; patient selection criteria for tailored approach and details of nodal treatment variation not available. Registry-based observational study; patient selection may differ from broader populations. Long-term follow-up data for competing approaches needed for direct comparison. Summary based on abstract only.

Source: MedPage Hematology/Oncology — 2026-03-30

Read more